| Literature DB >> 24321740 |
Katherine L Doll1, Noah S Butler2, John T Harty3.
Abstract
Sporozoite vaccination of both humans and rodents elicits potent anti-malarial immunity, but the dose of sporozoites and the number of immunizations required varies with vaccination approach. Here we examine the immunological basis for superior protection afforded from single-dose vaccination with virulent sporozoites administered under prophylatic chloroquine-cover, referred to as infection-treatment-vaccination (ITV), compared to the well-studied approach of administering radiation-attenuated Plasmodium sporozoites (RAS). Earlier rodent studies utilizing ITV and RAS vaccination suggested a major role of CD8 T cells in reducing liver parasite burden after sporozoite challenge in a BALB/c mouse model. Consistent with this, we find that in C57Bl/6 mice ITV elicits substantially higher parasite-specific CD8 T cell responses than RAS vaccination and enhances immunity against P. yoelii infection. However, we show ITV-induced CD8 T cells are not necessary for protection following liver-stage sporozoite or blood-stage parasite challenge. Mechanistically, we found protection afforded from single-dose ITV is associated with low grade, transient parasitemia shortly following cessation of chloroquine treatment and generation of potent antibody responses to blood-stage parasites. Collectively, our data show the mechanistic basis for enhanced protective immunity against P. yoelli elicited by ITV in highly susceptible C57Bl/6 mice is independent of CD8 T cells. These studies may be relevant in understanding the potent immunity observed with ITV in humans.Entities:
Keywords: Antibodies; B6; C57Bl/6; CD8 T cells; CQ; GAP; ITV; Plasmodium infections; Plasmodium yoelii 17XNL; Py; RAS; RBC; Subpatent infection; Vaccination; chloroquine; genetically attenuated parasites; infection-treatment vaccination; radiation-attenuated sporozoites; red blood cell
Mesh:
Substances:
Year: 2013 PMID: 24321740 PMCID: PMC3923319 DOI: 10.1016/j.vaccine.2013.11.058
Source DB: PubMed Journal: Vaccine ISSN: 0264-410X Impact factor: 3.641